Exelixis Inc

EXEL remains in a Stage 2 advancing uptrend with higher highs and higher lows intact. After a corrective pullback into the rising 9EMA and 21EMA, price has accepted key dynamic support and is holding above the 50DMA, presenting a favorable entry now. Medium-term bias stays bullish under controlled pullbacks, and long-term trend remains strong above the 200DMA. We engage now on pullback acceptance into dynamic support.

• ↑Cabozantinib U.S. revenues rose 36% YoY to $513M in Q1 2026
• ↑Consensus FY 2026 EPS estimates raised to $3.53, driven by strong revisions
• ↓Negative book-to-price ratio indicates potential overvaluation